RXRX · Healthcare

Recursion Pharmaceuticals Inc

USA Healthcare Filing: 2026-06-30

27/100

Smart-money confidence1 of 3 sources positive

Below average interest

No standout activity across the feeds we track.

What this band has actually done: stocks scoring 0–25 beat the S&P 500 over the next three months 39.9% of the time, across 100,496 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this

Hedge funds

Congress

No data

Insiders

No data

Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. · how the score works

Market cap

$2.2B

Industry

Biotechnology

Sector

Healthcare

Exchange

NasdaqGS

About RECURSION PHARMACEUTICALS INC

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma;…

Who's behind the signal

Every informed buyer we can see on RXRX, across all three feeds.

Hedge funds · 7

Bridgewater Associates (Dalio) New position

ARK Invest (Cathie Wood) Increased +3%

AQR Capital Management Increased +73%

Baillie Gifford & Co Unchanged

D.E. Shaw & Co Decreased −18%

Citadel Advisors Decreased −79%

+1 more in the full breakdown below ↓

Congress · 0

No congressional trades on record.

Insiders

No significant Form 4 insider activity in the window.

Not a model pick — but on our radar. RECURSION PHARMACEUTICALS INC isn't in the top-10 model right now, but 7 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.

Investors

New positions

Increasing

Decreasing

Unchanged

Price History

Loading price data...

Return: High: Low:

Who's Holding This Stock

Position sizes and recent activity from tracked institutional investors

Bridgewater Associates (Dalio)

Trust weight: 1.3×

New position

% of portfolio

0.0%

Position change

NEW

0.0% of Bridgewater Associates's portfolio

ARK Invest (Cathie Wood)

Trust weight: 1.3×

Increased +3%

% of portfolio

1.0%

Position change

+3%

1.0% of ARK Invest's portfolio

AQR Capital Management

Trust weight: 1.0×

Increased +73%

% of portfolio

0.0%

Position change

+73%

0.0% of AQR Capital Management's portfolio

Baillie Gifford & Co

Trust weight: 1.4×

Unchanged

% of portfolio

0.1%

Position change

—

0.1% of Baillie Gifford & Co's portfolio

D.E. Shaw & Co

Trust weight: 1.0×

Decreased −18%

% of portfolio

0.0%

Position change

−18%

0.0% of D.E. Shaw & Co's portfolio

Citadel Advisors

Trust weight: 1.0×

Decreased −79%

% of portfolio

0.0%

Position change

−79%

0.0% of Citadel Advisors's portfolio

Millennium Management (Englander)

Trust weight: 1.0×

Decreased −30%

% of portfolio

0.0%

Position change

−30%

0.0% of Millennium Management's portfolio

Portfolio Allocation

How much of each investor's portfolio is allocated to RECURSION PHARMACEUTICALS INC

⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell RECURSION PHARMACEUTICALS INC or any security.

Get the Weekly Update

Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.

Also alert me when a politician or insider makes a major trade ($500K+)

Free forever · No spam · Unsubscribe anytime